HUP0201636A1 - Indol derivative as spla2 inhibitor and pharmaceutical composition containing it - Google Patents

Indol derivative as spla2 inhibitor and pharmaceutical composition containing it

Info

Publication number
HUP0201636A1
HUP0201636A1 HU0201636A HUP0201636A HUP0201636A1 HU P0201636 A1 HUP0201636 A1 HU P0201636A1 HU 0201636 A HU0201636 A HU 0201636A HU P0201636 A HUP0201636 A HU P0201636A HU P0201636 A1 HUP0201636 A1 HU P0201636A1
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
composition containing
spla2 inhibitor
indol derivative
indol
Prior art date
Application number
HU0201636A
Other languages
English (en)
Hungarian (hu)
Inventor
Michael Lyle Denney
John Michaeljr Morin
Daniel Jon Sall
Jason Scott Sawyer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUP0201636A1 publication Critical patent/HUP0201636A1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU0201636A 1998-05-01 1999-04-20 Indol derivative as spla2 inhibitor and pharmaceutical composition containing it HUP0201636A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8387398P 1998-05-01 1998-05-01

Publications (1)

Publication Number Publication Date
HUP0201636A1 true HUP0201636A1 (en) 2002-09-28

Family

ID=22181214

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201636A HUP0201636A1 (en) 1998-05-01 1999-04-20 Indol derivative as spla2 inhibitor and pharmaceutical composition containing it

Country Status (22)

Country Link
EP (1) EP1073440B1 (cg-RX-API-DMAC10.html)
JP (1) JP4459441B2 (cg-RX-API-DMAC10.html)
KR (1) KR20010071197A (cg-RX-API-DMAC10.html)
CN (1) CN1303290A (cg-RX-API-DMAC10.html)
AT (1) ATE280155T1 (cg-RX-API-DMAC10.html)
AU (1) AU755901B2 (cg-RX-API-DMAC10.html)
BR (1) BR9910149A (cg-RX-API-DMAC10.html)
CA (1) CA2331036A1 (cg-RX-API-DMAC10.html)
DE (1) DE69921314T2 (cg-RX-API-DMAC10.html)
EA (1) EA003277B1 (cg-RX-API-DMAC10.html)
ES (1) ES2230847T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20000738A2 (cg-RX-API-DMAC10.html)
HU (1) HUP0201636A1 (cg-RX-API-DMAC10.html)
ID (1) ID27812A (cg-RX-API-DMAC10.html)
IL (1) IL139203A0 (cg-RX-API-DMAC10.html)
NO (1) NO315940B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ507391A (cg-RX-API-DMAC10.html)
PL (1) PL344571A1 (cg-RX-API-DMAC10.html)
SK (1) SK16332000A3 (cg-RX-API-DMAC10.html)
TR (1) TR200003198T2 (cg-RX-API-DMAC10.html)
WO (1) WO1999056752A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200005561B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
WO2001044185A1 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Carbon monoxide-based synthesis of spla2 inhibitors
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
EP2154958A4 (en) * 2007-05-03 2011-05-04 Anthera Pharmaceuticals Inc TREATMENT OF HEART CIRCULATION DISEASES AND DYSLIPIDEMIA WITH INHIBITORS OF SECRETARY PHOSPHOLIPASE A2 (SPLA2) AND SPLA2 HEMMER COMBINATION THERAPIES
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
US20150335498A1 (en) * 2014-05-22 2015-11-26 The Procter & Gamble Company Heterogenous mass containing foam
US10729600B2 (en) 2015-06-30 2020-08-04 The Procter & Gamble Company Absorbent structure
PL3370664T3 (pl) 2015-11-04 2022-03-07 The Procter & Gamble Company Wyrób chłonny zawierający strukturę chłonną
WO2017079599A1 (en) 2015-11-04 2017-05-11 The Procter & Gamble Company Absorbent structure
WO2017079605A1 (en) 2015-11-04 2017-05-11 The Procter & Gamble Company Method for determining bunch compression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
EP1950200B1 (en) * 1994-04-01 2012-01-11 Eli Lilly And Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
CA2358492A1 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis

Also Published As

Publication number Publication date
NO20005477D0 (no) 2000-10-31
NO20005477L (no) 2000-10-31
WO1999056752A1 (en) 1999-11-11
JP4459441B2 (ja) 2010-04-28
ES2230847T3 (es) 2005-05-01
EP1073440A4 (en) 2002-07-17
AU755901B2 (en) 2003-01-02
DE69921314D1 (de) 2004-11-25
DE69921314T2 (de) 2006-02-09
IL139203A0 (en) 2001-11-25
PL344571A1 (en) 2001-11-05
JP2002513761A (ja) 2002-05-14
EP1073440A1 (en) 2001-02-07
BR9910149A (pt) 2001-10-02
AU3652599A (en) 1999-11-23
EA200001141A1 (ru) 2001-04-23
KR20010071197A (ko) 2001-07-28
NO315940B1 (no) 2003-11-17
SK16332000A3 (sk) 2001-06-11
ZA200005561B (en) 2002-01-10
ATE280155T1 (de) 2004-11-15
TR200003198T2 (tr) 2001-03-21
EA003277B1 (ru) 2003-04-24
ID27812A (id) 2001-04-26
NZ507391A (en) 2003-12-19
HRP20000738A2 (en) 2001-10-31
CA2331036A1 (en) 1999-11-11
EP1073440B1 (en) 2004-10-20
CN1303290A (zh) 2001-07-11

Similar Documents

Publication Publication Date Title
HUP0000167A3 (en) Pyrroles as spla2 inhibitors, and pharmaceutical compositions containing them
SI1174431T1 (sl) 2-fenil-substituirani imidazotriazinoni kot inhibitorji fosfodiesteraze
HUP0101146A3 (en) Indole derivatives as inhibitors of phospholipase enzymes and pharmaceutical compositions containing them
HUP0100757A3 (en) Indole derivatives as inhibitors of phospholipase enzymes and pharmaceutical compositions containing them
AU8030598A (en) Indole compounds as cox-2 inhibitors
HUP0104768A3 (en) 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
IL147970A0 (en) Pharmaceutical compositions containing tripeptides
HUP0103366A3 (en) Amide derivatives which are useful as cytokine inhibitors
IL130111A0 (en) 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors
EG24117A (en) Dispersion formulations containing lipase inhibitors
IL140862A0 (en) Thiobenzimidazole derivatives and pharmaceutical compositions containing the same
PT1121116E (pt) Composição farmacêutica de libertação sustentada de fluvastatina
HUP0002951A3 (en) Bis-aminomethylcarbonyl compounds as protease inhibitors and pharmaceutical compositions containing them
GB9927315D0 (en) Inhibitor compositions
GB9827391D0 (en) Aldose reductase inhibitors and pharmaceutical compositions
HUP0100680A3 (en) Indole derivatives and medicinal compositions containing the same
AU2001267823A1 (en) Compounds exhibiting x-type spla2 inhibiting effect
EP1100493A4 (en) SPLA 2 INHIBITORS? OF THE INDOLTYPS
HUP9901984A3 (en) Naphthyl acetamides as spla2 inhibitors, use thereof and pharmaceutical compositions containing these compounds
EP1144305A4 (en) NEW sPLA 2 INHIBITORS
EP1238095A4 (en) COMPOSITIONS AND METHODS FOR CASPASE-INDUCED APOPTOSIS
HUP0103113A3 (en) New pharmaceutical compositions uses for nos inhibitors
EP1030661A4 (en) N, N-DIETHYLGLYCOLAMIDOESTER OF INDOLS AS PRELIMINARY MEDICINE OF SPLA 2 INHIBITORS
AU2001280461A1 (en) Substituted pyrrole compounds and their use as spla2 inhibitors
HUP0202732A3 (en) Amide compounds and pharmaceutical compositions containing them